email

Email:

info@biotech-pack.com

Free Quote
百泰派克蛋白质测序
百泰派克蛋白质组学服务
百泰派克生物制药分析服务
百泰派克代谢组学服务

Customized Host Cell Protein Profiling Solution for Biopharmaceutical Projects

With the rapid development of the biopharmaceutical industry, high-value-added drugs such as recombinant protein drugs, monoclonal antibodies, and fusion proteins are playing increasingly important roles in clinical settings. However, during the research and production of these biologics, host cell proteins (HCPs), which are impurities produced by the expression system itself, may remain in trace amounts in the final formulation after product purification. Despite their extremely low content, the immunogenicity, enzymatic activity, or nonspecific interaction of HCPs with the drug substance can pose threats to the safety, stability, and efficacy of the drug. Therefore, comprehensive, accurate, and traceable quantitative analysis of HCPs has become a key aspect of quality control systems in biologics. The most commonly used detection methods, such as ELISA, offer high throughput and good reproducibility but are limited by the antibody recognition principle, resulting in restricted antibody coverage and difficulty in identifying unknown or structurally altered HCPs. In contrast, mass spectrometry-based host cell protein profiling (HCP profiling by LC-MS/MS) is gradually becoming an important technical means for biopharmaceutical companies to assess the risk of HCP residues due to its unbiased, quantitative, and traceable advantages.

 

1. What are Host Cell Proteins (HCP) and their risks

HCPs are non-target proteins naturally produced by host cells in recombinant protein expression systems and may remain in the drug product after downstream purification. These proteins may originate from cytoplasmic components after cell lysis, extracellular secretions, or endogenous enzymes released due to stress, apoptosis, and other induction mechanisms.

The impact of HCP residues on drugs is mainly reflected in three aspects:

1. Induction of immune response:Some HCPs have strong immunogenicity, which may trigger patient drug resistance or adverse reactions.

2. Interference with drug efficacy:Certain HCPs can bind non-specifically with drug proteins, reducing their activity or altering their distribution in the body.

3. Impact on stability:HCPs with hydrolase or redox activity may accelerate drug degradation, shortening shelf life.

Therefore, the detection and risk assessment of HCPs are not only quality control requirements in biologic drug development but also crucial for ensuring patient drug safety.

 

2. Mainstream HCP detection methods and technological evolution

Current technologies for HCP detection mainly include ELISA, two-dimensional gel electrophoresis (2D-PAGE), and liquid chromatography-tandem mass spectrometry (LC-MS/MS), each with its own advantages and disadvantages.

1、ELISA:The most commonly used detection method relies on anti-HCP polyclonal antibodies for target protein recognition and quantification. This method offers high throughput and ease of operation, suitable for batch monitoring at the production release stage. However, due to limited antibody coverage, ELISA cannot identify low-abundance or novel HCPs not recognized by immune responses, posing a risk of missed detection.

 

2. Two-dimensional gel electrophoresis (2D-PAGE):Combining isoelectric focusing and SDS-PAGE separation of proteins, along with staining and imaging to observe changes in the HCP profile. This method can intuitively reflect HCP change trends, but its sensitivity and resolution are limited, and it cannot achieve precise quantification.

 

3. LC-MS/MS-based method:Using proteomics techniques, this method can achieve full-spectrum scanning and quantitative analysis of HCPs without relying on antibodies, capable of identifying low-abundance, variant, and even unknown HCPs. With the aid of high-resolution mass spectrometers and efficient database search algorithms, this method can significantly enhance detection coverage and reproducibility, becoming a powerful tool for HCP risk assessment and regulatory submissions.

 

In practical applications, mass spectrometry methods and ELISA often complement each other: ELISA is used for routine release monitoring, while mass spectrometry provides in-depth support during early development and process optimization stages.

 

3. Advantages of customized host cell protein profiling solutions

In the context where standardized methods cannot meet the individual process and expression system differences, customized HCP analysis solutions are especially critical.

Bio-Techne offers differentiated advantages in customized host cell protein profiling in the following three aspects:

  • Capability to construct databases adapted to various host systems
  • Support for dynamic monitoring at multiple time points/process nodes
  • Full-process support to meet regulatory compliance requirements


In today's era of biopharmaceuticals gradually moving towards personalization, quality-driven approaches, and globalization, the quantitative identification and risk management of host cell proteins have become one of the fundamental aspects of quality control throughout the drug lifecycle. Host cell protein profiling based on mass spectrometry, with its comprehensiveness, accuracy, and customizability, is becoming an important choice for new drug development and production companies. Bio-Techne is committed to providing highly sensitive and high-coverage customized HCP analysis services to assist clients in accurately identifying risk points during early development, enhancing process quality stability, and accelerating drug registration and submission efficiency. If you have more technical questions regarding HCP analysis, please feel free to contact our scientific service team for a one-on-one solution.

 

Bio-Techne — A leading provider of bioproduct characterization and multi-omics mass spectrometry detection services

 

Related services:

Host Cell Protein (HCP) Residual Analysis Services

Submit Inquiry
Name *
Email Address *
Phone Number
Inquiry Project *
Project Description*

 

How to order?